High Fiber Rye Foods for Weight and Body Fat Reduction

Obesity Clinical Trial

— RyeWeight  

Official title:

High Fiber Rye Foods for Weight and Body Fat Reduction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03097237
• Other study ID #: SLU254
• Status: Completed
• Phase: N/A
• Start date: September 2016
• Est. completion date: December 2018

Study information

• Verified date: January 2019
• Source: Swedish University of Agricultural Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall aim of this study is to investigate whether a diet rich in rye fiber from wholegrain rye, compared to refined wheat, as part of a hypocaloric diet leads to larger weight loss and lower body fat content after 12 weeks of intervention. Furthermore the study will investigate the effect on appetite as a potential underlying mechanism for differences in weight loss and body fat reduction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 242
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• BMI 27-35 kg/m2

• Hb=120g/l

• Serum thyroid stimulating hormone (TSH) =4.00 mIU/L

• Plasma low density lipoprotein cholesterol <5.3 mmol/L

• Plasma triglycerides =1.8 mmol/L

• Signed informed consent

• Freezer capacity for 2 weeks bread provision

Exclusion Criteria:

• Blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study

• Unable to complete satisfactorily the 3-day weighted food record at screening visit 2.

• Unable to lose 0.5 kg or more during the run-in period for men and women not having menstruation during the run in period

• Increased body weight, despite reported adherence to dietary intake for women with menstruation during the run-in period.

• Using nicotine products on a daily basis (incl. chewing gum, patches, snus etc.)

• Using e-cigarettes (regardless of nicotine content)

• Following any weight reduction program or having followed one during the last 6 months prior to visit 1

• Diastolic blood pressure 105 mm Hg at visit 1

• Systolic blood pressure 160 mm at visit 1

• History of stomach or gastrointestinal conditions (Inflammatory bowel disease, Crohn's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery etc.)

• More than 10 hours physical activity per week

• History of heart failure or heart attack within 1 year prior to screening

• Have type I diabetes

• Receiving pharmacological treatment for type II diabetes (treatments based on life style interventions are acceptable, as long as they are compatible with the study protocol)

• Previous gastrointestinal surgery

• Thyroid disorder

• History of drug or alcohol abuse

• Stroke or transient ischemic attack (TIA) within 1 year prior to screening

• Consumption of drugs aimed at weight management or drugs affecting body weight to a degree that is considered unsuitable for study participation by responsible physician (will be included in the list of allowed/disallowed medications)

• Pregnant or lactating or wish to become pregnant during the period of the study.

• Food allergies or intolerances

• Vegetarian (due to the standardized meals for appetite measurements)

• Unable to understand written and spoken Swedish

• Lack of suitability for participation in the trial, for any reason, as judged by the medical doctor or PI.

Related Conditions & MeSH terms

• Obesity
• Overweight

Intervention

Other:
• Wholegrain rye
Cereal products based on wholegrain rye
• Refined wheat
Cereal products based on refined wheat

Locations

Country	Name	City	State
Sweden	Chalmers University of Technology	Gothenburg

Sponsors (1)

Lead Sponsor	Collaborator
Swedish University of Agricultural Sciences

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in body weight		12 weeks
Primary	Difference in body fat mass		12 weeks
Secondary	Appetite measured by visual analogue scale (VAS) questionnaire	Investigate if satiety differs between groups after 12 weeks of intervention and investigate if appetite correlates with changes in body weight. Measurements will be conducted through visual analogue scale (VAS) questionnaire, where participants log into a homepage and respond to their perceived satiety, hunger and desire to eat every 30-60 min during a day at base line, after 6w and 12wk.	12 weeks
Secondary	Difference in body weight and body fat mass	Investigate if differences in body weight and body fat mass is evident already after 6 weeks	6 weeks
Secondary	Fecal energy excretion by bomb calorimetry of 72h quantitative fecal collections.	Investigate differences in fecal energy excretion between the two intervention groups in a subgroup of 50 subjects. Every subject will be instructed to collect all feces in a special devise during 48h.	12 weeks
Secondary	Gut microbiota		6 and 12 weeks
Secondary	Marker of glucose metabolism	Investigate differences in hemoglobin A1c (HbA1c)	6 and 12 weeks
Secondary	Marker of Insulin resistance	Investigate differences in homeostatic model assessment insulin resistance (HOMA-IR)	6 and 12 weeks
Secondary	Appetite regulation	Investigate differences in glucagon-like peptide 1(GLP-1)	6 and 12 weeks
Secondary	Appetite	Investigate differences in leptin concentration	6 and 12 weeks
Secondary	Marker of inflammation	Investigate differences in C-reactive protein (CRP).	6 and 12 weeks
Secondary	Blood lipids	Investigate differences in triglyceride (TG), total cholesterol, high density lipoprotein(HDL) and low density lipoprotein (LDL).	6 and 12 weeks